Search the Newsreel

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15

H.C. Wainwright has reiterated its Buy rating for Unicycive Therapeutics (UNCY.US) and maintained a price target of $15. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages

Unicycive Therapeutics (NASDAQ:UNCY) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $21.75, despite recent target reductions and downgrades from some firms. The company reported a quarterly loss of $0.06 per share, beating analyst estimates, and institutional …

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics reported its second-quarter 2026 financial results, with $61.4 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The company is focused on securing FDA approval for oxylanthanum carbonate (OLC) for hyperphosphatemia, with a facility inspection assigned for their …

Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside

Analysts have cut the average 12-month price target for Unicycive Therapeutics, Inc. (UNCY) stock from $37.5 to $32.5, with individual forecasts ranging from $13 to $61 per share. Despite the cut, the new target still implies a significant 550% potential upside based on the …

Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results

Unicycive Therapeutics (NASDAQ:UNCY) reported a quarterly loss of $0.06 per share, significantly beating analyst expectations of a $0.47 loss. Following the positive earnings surprise, shares of UNCY traded up, and institutional investors have increased their holdings. Analyst sentiment remains mixed with a consensus "Hold" …

Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com

This article reports on the filing of a Form 8K by Unicycive Therapeutics Inc. on August 12. The brief announcement from Investing.com provides the date of the filing and the company name. The rest of the content includes market data, news headlines, and promotional …

Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

Unicycive Therapeutics' shares rose after reporting a smaller-than-expected second-quarter loss of $0.06 per share, significantly beating the analyst consensus of $0.48 per share. The net loss narrowed to $1.7 million from $6.5 million due to a change in warrant liability fair value, despite increased …

Unicycive Therapeutics stock rises 2% on second quarter earnings beat

Unicycive Therapeutics (UNCY) posts $14.5M H1 loss, raises $34M equity

Unicycive Therapeutics reported a net loss of $14.5 million for the first half of 2026, widening from $5.9 million in the prior year, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its …

Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection

Unicycive Therapeutics announced its Q2 2026 financial results, reporting $61.4 million in cash and securities, expected to fund operations into 2027. The company's lead drug, oxylanthanum carbonate (OLC), received a Complete Response Letter from the FDA due to third-party manufacturing deficiencies, but the FDA …

Unicycive Therapeutics (UNCY) Earnings Date and Reports 2026

Unicycive Therapeutics Inc (UNCY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Unicycive Therapeutics Inc (UNCY) Stock News Today

The article provides a current snapshot of Unicycive Therapeutics Inc (UNCY) stock, including its trading price, market cap, and a note that more news is coming soon. It indicates that the stock closed at $5.070, up 0.40%, with a market capitalization of $127.96 million. …

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday

Unicycive Therapeutics (NASDAQ:UNCY) is expected to announce its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting a loss of $0.471 per share and revenue of $22.2 million. This follows a Q1 loss of $0.54 per share, which missed estimates. …

UNCY|Unicycive Therapeutics Inc|Price:5.285|Chg%:+0.545

This article provides a comprehensive stock analysis of Unicycive Therapeutics Inc (UNCY) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Despite healthy fundamentals and significant growth potential, the stock is considered fairly valued and …

BlackRock (UNCY holder) reports 5.3% Unicycive Therapeutics stake in Schedule 13G

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership stake of 5.3% in Unicycive Therapeutics, Inc. This stake amounts to 1,413,381 shares of common stock, with BlackRock holding sole voting power over 1,391,049 shares and sole dispositive power over all 1,413,381 shares. …

Unicycive Therapeutics Inc Today's Market Trends | UNCY Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

Unicycive Therapeutics Inc (UNCY) is a biotechnology company focused on kidney disease treatments, with lead drug candidate oxylanthanum carbonate (OLC) and UNI-494 in development. Despite strong fundamentals and significant institutional ownership, the stock has shown weak market performance and is currently trading sideways. Analysts, …

Unicycive Therapeutics (UNCY) grants 47,941 RSUs to director Laumas

Unicycive Therapeutics director Sandeep Laumas was granted 47,941 restricted stock units (RSUs) on May 14, 2026, as reported in a Form 4/A filing. Of these, 19,976 RSUs vested upon grant, and the remaining 3,995 units will vest monthly over seven months, subject to his …

Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting

Unicycive Therapeutics director Sara Kenkare-Mitra was granted 47,941 Restricted Stock Units (RSUs) on May 14, 2026. Of these, 19,976 shares vested immediately, and the remaining 3,995 shares will vest monthly over seven months, starting June 1, 2026, contingent upon her continued service. The transaction, …

Unicycive Therapeutics Inc (UNCY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Unicycive Therapeutics Inc (UNCY), noting its current valuation score of 6.30, which ranks 341 out of 386 in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.28, significantly below its recent high. Key …

Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY

This page provides financial information for Unicycive Therapeutics, Inc. (UNCY) on the Nasdaq Stock Market. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment breakdown options. The content itself seems to be a template for financial data presentation …

Unicycive Therapeutics Inc (UNCY) Cash Flow

This article provides a detailed look at Unicycive Therapeutics Inc's (UNCY) cash flow statements, including operating, investing, and financing activities, spanning from FY2019Q4 to FY2026Q1. It presents quarterly and annual financial data, highlighting changes in net income, working capital, capital expenditures, and cash balances …

Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Unicycive Therapeutics Inc's (UNCY) shareholder structure, listing major shareholders by proportion and categorizing shareholders by type such as hedge funds and venture capital. It also presents institutional shareholding trends over several quarters, showing changes in the number …

UNCY|Unicycive Therapeutics Inc|Price:5.410|Chg%:-0.050

Unicycive Therapeutics Inc (UNCY) is a biotechnology company focused on developing treatments for kidney diseases, with its lead drug candidate, oxylanthanum carbonate (OLC), targeting hyperphosphatemia in dialysis patients, and UNI-494 for acute kidney injury. The article provides current stock information, company details including key …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Unicycive Therapeutics, Inc. (UNCY) following a significant drop in its stock price. This investigation comes after the FDA issued a second Complete Response Letter regarding the company's kidney disease therapy, oxylanthanum, citing unresolved third-party …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Unicycive Therapeutics, Inc. (UNCY) after the FDA issued a second Complete Response Letter for its kidney disease therapy, oxylanthanum, citing unresolved manufacturing deficiencies. The law firm is encouraging investors who purchased Unicycive securities to join their investigation …

Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Unicycive Therapeutics, Inc. following a stock drop. This investigation stems from the FDA issuing a second Complete Response Letter for Unicycive's kidney disease therapy, citing manufacturing deficiencies. The law firm is encouraging investors …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Unicycive Therapeutics, Inc. (UNCY) following a significant drop in its stock price. This investigation comes after the FDA issued a second Complete Response Letter for Unicycive's kidney disease therapy, oxylanthanum, citing unresolved third-party manufacturing …

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $30.00 price target, despite the company's recent quarterly GAAP net loss of $12.82 million. The Street maintains a Strong Buy consensus with an average price target of $36.71. Benchmark …